Alto Neuroscience, Inc. Cash Flow Conversion Efficiency
Alto Neuroscience, Inc. cash flow conversion efficiency. Based on the latest financial reports, Alto Neuroscience, Inc. (ANRO) has a cash flow conversion efficiency ratio of -0.076x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.52 Million) by net assets ($151.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Alto Neuroscience, Inc. (2021–2025)
Cash flow conversion efficiency of Alto Neuroscience, Inc. from 2021 to 2025. This chart illustrates how Alto Neuroscience, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Alto Neuroscience, Inc. (ANRO) share price today for real-time trading data and today's change.
Alto Neuroscience, Inc. Cash Flow Conversion Ratio Explained
Alto Neuroscience, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alto Neuroscience, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alto Neuroscience, Inc. ranked by their cash flow conversion efficiency. Also see ANRO market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AIC Inc
TWO:3693
|
-0.079x |
|
Dharma Satya Nusantara Ptdsn
JK:DSNG
|
0.053x |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
0.020x |
|
Guangzhou Pearl River Piano Group Co Ltd
SHE:002678
|
-0.021x |
|
Zbit Semiconductor Inc. A
SHG:688416
|
N/A |
|
PROSEGUR CASH UNSP.ADR/5
F:PQD0
|
N/A |
|
Beijing Watertek Information Technology Co Ltd
SHE:300324
|
0.004x |
|
Dashang Co Ltd
SHG:600694
|
0.006x |
Annual Cash Flow Conversion Efficiency for Alto Neuroscience, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Alto Neuroscience, Inc. from 2021 to 2025. Review how financially flexible is Alto Neuroscience, Inc. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $151.14 Million | $-51.77 Million | -0.343x | -9.39% |
| 2024-09-30 | $151.46 Million | $-47.42 Million | -0.313x | -167.09% |
| 2023-09-30 | $-71.67 Million | $-33.45 Million | 0.467x | -12.11% |
| 2022-09-30 | $-38.41 Million | $-20.39 Million | 0.531x | -28.46% |
| 2021-09-30 | $-12.48 Million | $-9.26 Million | 0.742x | -- |
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clini… Read more